Beta-2 Microglobulin Biomarker for PAD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peripheral artery disease (PAD) is often underdiagnosed and undertreated due to the lack of effective screening methods in primary care settings, as current methods like the ankle-brachial index (ABI) require specialized equipment and training, and are prone to false negatives in diabetic patients.
Innovation Solution
A method involving the measurement of β2-microglobulin levels in biological samples using techniques such as mass spectrometry or immunoassay, potentially combined with other biomarkers like cystatin C and lysozyme, to assess and manage PAD, including predicting treatment responsiveness and disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the ankle-brachial index (ABI) is used to screen for PAD, then PAD can be detected, but the method requires specialized equipment and training and is not accessible in primary care settings
Solution Approach 1:
The patent replaces the mechanical/physical ABI measurement system (requiring Doppler ultrasound equipment and trained technicians) with a biochemical diagnostic system using blood biomarkers. This substitution enables PAD screening in primary care settings without specialized equipment, as the biomarker test can be performed using standard laboratory infrastructure.
Solution Approach 2:
The patent introduces blood biomarkers (such as beta-2 microglobulin, cystatin C, and lysozyme) as intermediary substances that mediate the detection of PAD. Instead of directly measuring vascular function through ABI, the test measures these intermediary biomarkers in blood, which reflect the underlying atherosclerotic process and enable indirect diagnosis of PAD.
2Reliability
If the ankle-brachial index (ABI) is used to screen for PAD, then PAD can be detected, but the method is prone to false negatives in diabetic patients
Solution Approach 1:
The patent changes the diagnostic parameter from mechanical vascular resistance (ABI) to biochemical markers (blood biomarkers). This parameter change allows for more accurate PAD detection in diabetic patients because the biomarkers reflect the underlying atherosclerotic pathology rather than being influenced by vascular stiffness and compression issues that cause false negatives in ABI testing for diabetics.
3Ease of operation
If blood tests for PAD biomarkers are implemented, then PAD can be detected in primary care settings, but the cost of the test must be considered
Solution Approach 1:
The patent employs blood biomarkers that can be measured using universal laboratory infrastructure already present in primary care settings. The same biochemical testing capabilities used for routine blood work can measure PAD biomarkers, eliminating the need for separate specialized testing facilities and reducing overall implementation costs compared to deploying dedicated ABI equipment throughout primary care networks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the early detection and management of PAD, reducing the risk of cardiovascular events and improving patient outcomes by providing a simple, accessible blood test for identifying PAD in clinical settings.
Implementation Method 1
measuring β2-microglobulin in a biological sample from the subject. In one embodiment, the β2-microglobulin is measured by mass spectrometry.
Implementation Method 2
the β2-microglobulin, cystatin C or lysozyme measurements are obtained by an immunoassay.
Data Source
AI summary
The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.